Novartis Korea and Hanmi Pharmaceutical signed a strategic partnership for the sales of type 2 diabetes treatment 'Galvus' and 'Galvusmet’
Novartis Korea and Hanmi Pharmaceutical signed a strategic partnership for the sales of type 2 diabetes treatment 'Galvus (vildagliptin)' and 'Galvusmet (vildagliptin / metformin)'.
Both companies' executive staffs attended the celebration for the strategic partnership and assured that they will...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
